XML 44 R31.htm IDEA: XBRL DOCUMENT v3.21.1
Collaboration Agreements and Revenues - Summary of Revenue Recognized Under the Collaboration Agreements - Additional Information 4 (Detail)
$ in Millions
3 Months Ended
Mar. 31, 2021
USD ($)
Europe [Member]  
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]  
Remainder of transaction price, variable consideration from estimated future co-development billing $ 24.5
Europe [Member] | Astellas Agreement [Member]  
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]  
Changes in revenue from changes to estimated variable consideration 0.4
U.S./RoW and China [Member]  
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]  
Remainder of transaction price, variable consideration from estimated future co-development billing 49.5
U.S./RoW and China [Member] | AstraZeneca Agreements [Member]  
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]  
Changes in revenue from changes to estimated variable consideration $ 4.2